<?xml version="1.0" encoding="utf-8"?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:og="http://ogp.me/ns#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:schema="http://schema.org/" xmlns:sioc="http://rdfs.org/sioc/ns#" xmlns:sioct="http://rdfs.org/sioc/types#" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" version="2.0" xml:base="http://www.itnonline.com/">
  <channel>
    <title>Imaging Technology News</title>
    <link>http://www.itnonline.com/</link>
    <description/>
    <language>en</language>
    
    <item>
  <title>Neurophet, RapidAI Team Up to Expand Access to Alzheimer’s, MS Treatment Monitoring</title>
  <link>http://www.itnonline.com/content/neurophet-rapidai-team-expand-access-alzheimer%E2%80%99s-ms-treatment-monitoring</link>
  <description>
      &lt;div class="field field--name-field-image field--type-image field--label-hidden field--items"&gt;
              &lt;div class="field--item"&gt;  &lt;img loading="lazy" src="http://www.itnonline.com/sites/default/files/RadpidAI%20new%20logo%20sq_1.png" width="300" height="300" alt="Neurophet, RapidAI Team Up to Expand Access to Alzheimer’s, MS Treatment Monitoring" title="Neurophet, RapidAI Team Up to Expand Access to Alzheimer’s, MS Treatment Monitoring" typeof="foaf:Image" class="img-responsive" /&gt;&lt;/div&gt;
          &lt;/div&gt;
  

&lt;span&gt;&lt;span lang="" about="http://www.itnonline.com/users/timhodson" typeof="schema:Person" property="schema:name" datatype="" xml:lang=""&gt;tim.hodson&lt;/span&gt;&lt;/span&gt;

&lt;span&gt;Wed, 11/04/2026 - 16:18&lt;/span&gt;

            &lt;div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"&gt;&lt;p&gt;Nov. 2, 2026 — Neurophet and &lt;a href="https://www.rapidai.com/"&gt;RapidAI&lt;/a&gt; have partnered to integrate Neurophet’s advanced neurodegenerative brain imaging solutions into the Rapid Enterprise Platform.&lt;/p&gt;
&lt;p&gt;The partnership will accelerate commercialization of the globally established Neurophet solution into the U.S. market by integrating into RapidAI’s platform. The Neurophet comprehensive brain imaging analysis solution includes Neurophet AQUA AD Plus and Neurophet SCALE PET, designed to support the prescription of Alzheimer’s disease treatments, brain health, and dementia patient management.&lt;/p&gt;
&lt;p&gt;The portfolio also includes Neurophet AQUA MS, a quantitative imaging analysis software solution for multiple sclerosis (MS). Integrated into Neurophet AQUA, Neurophet AQUA MS analyzes brain images of patients with MS, an intractable disease of the central nervous system.&lt;/p&gt;
&lt;p&gt;Neurophet AQUA AD Plus uses AI-powered brain magnetic resonance imaging (MRI) analysis to automatically identify and quantify the locations and number of hypointense lesions associated with cerebral microbleeds and superficial siderosis, as well as hyperintense lesions associated with brain edema.&lt;/p&gt;
&lt;p&gt;These imaging findings are particularly important for monitoring potential treatment-related side effects in patients with Alzheimer's disease receiving anti-amyloid therapies, such as Leqembi and Kisunla. By providing quantitative insights into these brain changes, the solution seeks to support clinicians in assessing treatment safety and making more informed decisions throughout the course of Alzheimer's disease treatment.&lt;/p&gt;
&lt;h4&gt;Combining RapidAI, Neurophet Expertise&lt;/h4&gt;
&lt;p&gt;By combining RapidAI’s established U.S. hospital and healthcare customer base with Neurophet’s AI-powered brain imaging technology, the companies aim to expand access to advanced neuroimaging solutions and support more informed clinical decision-making.&lt;/p&gt;
&lt;p&gt;“We plan to complete the integration of Neurophet AQUA AD Plus into RapidAI and begin full-scale product distribution, focusing on memory disorders centers in the U.S. that prescribe Leqembi and Kisunla,” said Jake Junkil Been, Co-CEO of Neurophet.&lt;/p&gt;
&lt;p&gt;He added, “We will further expand the platform integration to include Neurophet AQUA and Neurophet SCALE PET, establishing a comprehensive solution delivery framework that covers the entire continuum of dementia care, from diagnosis to treatment monitoring.”&lt;/p&gt;
&lt;p&gt;Through the Rapid Enterprise Platform, Neurophet's advanced neuroimaging capabilities are integrated into the workflows radiologists and care teams already use. Radiologists will be able to access AI-generated insights through Rapid Navigator Pro, while clinicians can access results through the Rapid Mobile App, helping teams review findings and coordinate patient care.&lt;/p&gt;
&lt;p&gt;The integration reflects RapidAI's deep expertise and commitment to continued innovation across the neuroscience service line. It gives health systems a consistent way to access and manage specialized clinical AI solutions through shared infrastructure and centralized AI governance. Together, these capabilities aim to support more informed treatment decisions and longitudinal monitoring for patients with neurodegenerative diseases.&lt;/p&gt;
&lt;p&gt; &lt;/p&gt;
&lt;p&gt;&lt;img alt="RapidAI" data-entity-type="file" data-entity-uuid="9887aa11-9bf9-4748-b0de-3fee2b4e3ff7" height="26" src="http://www.itnonline.com/sites/default/files/inline-images/RapidAI%20logo%20new_0.png" width="75" class="align-center" /&gt;&lt;/p&gt;&lt;p&gt; &lt;/p&gt;
&lt;/div&gt;
      
            &lt;div class="field field--name-field-publication-date field--type-datetime field--label-hidden field--item"&gt;&lt;time datetime="2026-11-04T22:18:24Z"&gt;Wednesday, November 4, 2026 - 16:18&lt;/time&gt;&lt;/div&gt;
      </description>
  <pubDate>Wed, 04 Nov 2026 22:18:24 +0000</pubDate>
    <dc:creator>tim.hodson</dc:creator>
    <guid isPermaLink="false">91312 at http://www.itnonline.com</guid>
    </item>
<item>
  <title>GE HealthCare Expands Vscan Air AI Capabilities with Lung Guidance and AutoAS</title>
  <link>http://www.itnonline.com/content/ge-healthcare-expands-vscan-air-ai-capabilities-lung-guidance-and-autoas</link>
  <description>
      &lt;div class="field field--name-field-image field--type-image field--label-hidden field--items"&gt;
              &lt;div class="field--item"&gt;  &lt;img loading="lazy" src="http://www.itnonline.com/sites/default/files/GE%20HealthCare%20Lung%20Guidance%20on%20tablet.jpg" width="300" height="210" alt="GE HealthCare Expands Vscan Air AI Capabilities with Lung Guidance and AutoAS" title="GE HealthCare Expands Vscan Air AI Capabilities with Lung Guidance and AutoAS" typeof="foaf:Image" class="img-responsive" /&gt;&lt;/div&gt;
          &lt;/div&gt;
  

&lt;span&gt;&lt;span lang="" about="http://www.itnonline.com/users/timhodson" typeof="schema:Person" property="schema:name" datatype="" xml:lang=""&gt;tim.hodson&lt;/span&gt;&lt;/span&gt;

&lt;span&gt;Tue, 11/03/2026 - 13:58&lt;/span&gt;

            &lt;div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"&gt;&lt;p&gt;Nov. 3, 2026 — &lt;a href="http://www.gehealthcare.com"&gt;GE HealthCare &lt;/a&gt;has announced two new AI-assisted capabilities for its Vscan Air handheld ultrasound system: Lung Guidance and AutoAS.&lt;sup&gt;1&lt;/sup&gt; Designed for clinicians evaluating patients with cardiac and respiratory symptoms at the point of care, these innovations are intended to support consistent lung ultrasound image acquisition and provide additional insights for the assessment of moderate-to-severe aortic stenosis (AS).&lt;/p&gt;
&lt;p&gt;Patients presenting with symptoms such as shortness of breath can require clinicians to consider cardiac, pulmonary or overlapping causes, often in time-pressured settings where formal imaging or specialist interpretation may not be immediately available. The Vscan Air cardiopulmonary suite of AI solutions, which already includes Caption AI for cardiac scan guidance and Caption Interpretation Auto EF (ejection fraction) interpretation support, now expands to assist users with Lung Guidance for pulmonary assessment support, and AutoAS for the assessment of valve disease. Together, the suite is designed to bring additional information closer to the initial point of assessment, helping clinicians build consistency, clarity and confidence as they determine appropriate next steps in care.&lt;/p&gt;
&lt;p&gt;“Clinicians at the point of care are often working with limited time and incomplete information, and a symptom like shortness of breath rarely announces if it’s coming from the heart, the lungs, or both,” said Karley Yoder, Chief Executive Officer, Ultrasound Solutions, Advanced Imaging Solutions, GE HealthCare. “Lung Guidance and AutoAS are designed to shorten the distance between the initial physical assessment and a clear next step, putting AI-enabled tools in the hands of the clinician who is already with the patient.”&lt;/p&gt;
&lt;h4&gt;More Consistent Lung Ultrasound Acquisition&lt;/h4&gt;
&lt;p&gt;Lung Guidance provides real-time scan guidance to help clinicians optimize probe position and acquire diagnostic-quality lung images by guiding them to correct anatomical landmarks in each zone of the standard 8-zone lung protocol. The system helps guide image acquisition through the detection of lung landmarks including the pleural line, A-lines, rib shadows, diaphragm and abdomen.&lt;/p&gt;
&lt;p&gt;When predefined landmark and image-quality criteria are met, AutoCapture automatically records an ultrasound clip. A Save Best Clip feature also allows users to retain the best quality image from each view during scanning when AutoCapture conditions are not achieved. Lung Guidance additionally supports B-line detection and scoring, as well as reporting to help clinicians organize findings from the acquired lung ultrasound exam.&lt;/p&gt;
&lt;p&gt;In validation testing, Lung Guidance enabled non-expert lung ultrasound users to consistently acquire diagnostic-quality lung ultrasound exams, with 95.2 percent success compared with 96.8 percent for expert users, per a descriptive assessment.&lt;sup&gt;2&lt;/sup&gt;&lt;/p&gt;
&lt;h4&gt;AI-assisted Aid&lt;/h4&gt;
&lt;p&gt;AutoAS is designed to provide an AI-assisted automated visual estimate of the presence or absence of moderate-to-severe AS using standard 2D cardiac images acquired with Vscan Air SL. With at least two compatible standard echocardiographic views—parasternal long-axis (PLAX), parasternal short-axis at the aortic valve (PSAX-AV) or apical five-chamber (AP5) — AutoAS analyzes the images and provides an estimate indicating whether findings are suggestive of moderate-to-severe AS, along with a confidence score indicating the algorithm’s certainty.&lt;/p&gt;
&lt;p&gt;AutoAS is designed to support a clinician’s early assessment of AS when access to formal echocardiography may be delayed.&lt;sup&gt;3&lt;/sup&gt;  AutoAS was trained and validated against a reference panel of expert cardiologists and can reduce the variability of missed AS compared to visual interpretation alone.&lt;sup&gt;4&lt;/sup&gt;&lt;/p&gt;
&lt;p&gt;Together, Lung Guidance and AutoAS build on Vscan Air’s existing AI capabilities, including Caption AI and Auto Bladder Volume, and reflect GE HealthCare’s efforts to support the confident use of ultrasound by more users. GE HealthCare continues to activate AI solutions across its extensive point-of-care ultrasound portfolio, including Venue™ family systems, LOGIQ™ e family and Vscan Air, meeting the needs of large healthcare systems, individual physicians, and everyone in-between.&lt;/p&gt;
&lt;p&gt;Lung Guidance and AutoAS are 510(k) cleared by the U.S. Food and Drug Administration and CE marked, and are available for purchase through Vscan Air Innovation Packages in the United States and select countries. Existing Vscan Air customers with a valid Innovation Package subscription or license are expected to receive these updates by the end of November 2026. Offerings vary by location and system model.&lt;/p&gt;
&lt;p&gt;For more information about Vscan Air, visit: &lt;a data-analytics-attached="true" data-analytics-event="linkTracking" data-analytics-json="{"linkName":"https://www.gehealthcare.com/en-us/products/ultrasound/handheld-ultrasound.","linkType":"Article Body Copy","linkTitle":""}" href="https://www.gehealthcare.com/en-us/products/ultrasound/handheld-ultrasound" rel="noopener noreferrer" target="_self"&gt;https://www.gehealthcare.com/en-us/products/ultrasound/handheld-ultrasound.&lt;/a&gt;&lt;/p&gt;
&lt;p&gt; &lt;/p&gt;
&lt;h4&gt;References&lt;/h4&gt;
&lt;ol&gt;&lt;li&gt;
&lt;p&gt;Only available on Vscan Air SL.&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;a data-analytics-attached="true" data-analytics-event="linkTracking" data-analytics-json="{"linkName":"","linkType":"Article Body Copy","linkTitle":""}" id="2"&gt;&lt;/a&gt;Lung Guidance, validation data – UM DOC3172170&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;AutoAS is intended as a diagnostic aid and not as a standalone diagnostic tool. Final clinical decisions remain the responsibility of the interpreting clinician and should be informed by comprehensive echocardiographic assessment and clinical judgment.&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;a data-analytics-attached="true" data-analytics-event="linkTracking" data-analytics-json="{"linkName":"","linkType":"Article Body Copy","linkTitle":""}" id="4"&gt;&lt;/a&gt;AutoAS, validation data – UM DOC3275253&lt;/p&gt;
&lt;/li&gt;
&lt;/ol&gt;&lt;p&gt;&lt;img alt="GE HealthCare Lung" data-entity-type="file" data-entity-uuid="5f69f237-0ae2-4c5e-8027-b44cc1329c47" height="72" src="http://www.itnonline.com/sites/default/files/inline-images/GE%20Healthcare%20New%202_0.png" width="75" class="align-center" /&gt;&lt;/p&gt;&lt;p&gt; &lt;/p&gt;
&lt;/div&gt;
      
            &lt;div class="field field--name-field-publication-date field--type-datetime field--label-hidden field--item"&gt;&lt;time datetime="2026-11-03T19:58:41Z"&gt;Tuesday, November 3, 2026 - 13:58&lt;/time&gt;&lt;/div&gt;
      
      &lt;div class="field field--name-field-company field--type-entity-reference field--label-hidden field--items"&gt;
              &lt;div class="field--item"&gt;
&lt;div id="node-99" data-history-node-id="99" role="article" about="http://www.itnonline.com/company/ge-healthcare" class="node node-company is-promoted default clearfix"&gt;
  
    

  
  &lt;div class="content"&gt;
     
      &lt;/div&gt;

&lt;/div&gt;

&lt;/div&gt;
          &lt;/div&gt;
  </description>
  <pubDate>Tue, 03 Nov 2026 19:58:41 +0000</pubDate>
    <dc:creator>tim.hodson</dc:creator>
    <guid isPermaLink="false">91311 at http://www.itnonline.com</guid>
    </item>
<item>
  <title>Corsmed Now Offering Free Tier to MRI Simulator</title>
  <link>http://www.itnonline.com/content/corsmed-now-offering-free-tier-mri-simulator</link>
  <description>
      &lt;div class="field field--name-field-image field--type-image field--label-hidden field--items"&gt;
              &lt;div class="field--item"&gt;  &lt;img loading="lazy" src="http://www.itnonline.com/sites/default/files/Corsmed%20Simulator.png" width="300" height="284" alt="Corsmed Now Offering Free Tier to MRI Simulator" title="Corsmed Now Offering Free Tier to MRI Simulator" typeof="foaf:Image" class="img-responsive" /&gt;&lt;/div&gt;
          &lt;/div&gt;
  

&lt;span&gt;&lt;span lang="" about="http://www.itnonline.com/users/timhodson" typeof="schema:Person" property="schema:name" datatype="" xml:lang=""&gt;tim.hodson&lt;/span&gt;&lt;/span&gt;

&lt;span&gt;Mon, 11/02/2026 - 16:04&lt;/span&gt;

            &lt;div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"&gt;&lt;p&gt;Nov. 2, 2026 — &lt;a href="http://www.corsmed.com"&gt;Corsmed&lt;/a&gt; has launched a free tier of its MRI simulator, making the platform available to any student or MRI professional worldwide  with no time limit.&lt;/p&gt;
&lt;p&gt;The free tier includes access to two of the most clinically common anatomies – head and knee – alongside eight core pulse sequences: Turbo Spin Echo (TSE), Spin Echo (SE), Gradient Echo (GRE), FLAIR, IR Spin-Echo, IR-TSE, Single-Shot Fast Spin Echo (SS-FSE), and MP-RAGE.&lt;/p&gt;
&lt;p&gt;Users access the same simulation engine as the full paid platform, meaning parameter changes produce the correct image effects (including artifacts, contrast, resolution, SNR, scan time, CNR, SAR), exactly as they would on a real scanner.&lt;/p&gt;
&lt;p&gt;The move removes a long-standing barrier in MRI education. Clinical scanners run on tight patient schedules, leaving students with limited hands-on practice time. Corsmed's simulator has addressed that gap for institutions since its launch, and the free tier extends that access to individuals regardless of their institution's budget or procurement capacity.&lt;/p&gt;
&lt;p&gt;"MRI training has always been held back by one problem: access," said Erik Jacobsson, CEO of Corsmed.&lt;/p&gt;
&lt;p&gt;"A student in an under-resourced program, or in a country where MRI equipment is scarce, deserves the same ability to practice as someone at a well-funded hospital. Making the simulator free is the most direct way we can act on that belief. "&lt;/p&gt;
&lt;h4&gt;MRI Simulator&lt;/h4&gt;
&lt;p&gt;The simulator is already live across the entire world, used by organisations such as NHS University College London Hospitals (UCLH), British Columbia Institute of Technology, and City St George’s University of London. UCLH has reported that new MRI radiographers now reach clinical competence in 3–4 months rather than 6.&lt;/p&gt;
&lt;p&gt;The full paid platform extends access to 60+ anatomies, 30+ pulse sequences, pathology simulation, advanced patient and scanner settings, and LMS integration for multi-student management. The free tier is designed as a genuine starting point, using the same true-to-life simulation engine throughout.&lt;/p&gt;
&lt;p&gt;Students and professionals can create a free account and start practicing at &lt;a href="http://corsmed.com/mri-simulator/free"&gt;corsmed.com/mri-simulator/free&lt;/a&gt;.&lt;/p&gt;
&lt;p&gt; &lt;/p&gt;
&lt;p&gt;&lt;img alt="Corsmed Free MRI Simulator" data-entity-type="file" data-entity-uuid="920c5a05-1d9b-4d29-80e2-9e4092bb9a81" height="71" src="http://www.itnonline.com/sites/default/files/inline-images/Corsmed%20Simulator%20sm.png" width="75" class="align-center" /&gt;&lt;/p&gt;&lt;p&gt; &lt;/p&gt;
&lt;/div&gt;
      
            &lt;div class="field field--name-field-publication-date field--type-datetime field--label-hidden field--item"&gt;&lt;time datetime="2026-11-02T22:04:19Z"&gt;Monday, November 2, 2026 - 16:04&lt;/time&gt;&lt;/div&gt;
      </description>
  <pubDate>Mon, 02 Nov 2026 22:04:19 +0000</pubDate>
    <dc:creator>tim.hodson</dc:creator>
    <guid isPermaLink="false">91310 at http://www.itnonline.com</guid>
    </item>
<item>
  <title>Clarius App Includes 30 Specialized Ultrasound AI Models </title>
  <link>http://www.itnonline.com/content/clarius-app-includes-30-specialized-ultrasound-ai-models</link>
  <description>
      &lt;div class="field field--name-field-image field--type-image field--label-hidden field--items"&gt;
              &lt;div class="field--item"&gt;  &lt;img loading="lazy" src="http://www.itnonline.com/sites/default/files/Clarius%20App.png" width="300" height="300" alt="Clarius App Includes 30 Specialized Ultrasound AI Models " title="Clarius App Includes 30 Specialized Ultrasound AI Models " typeof="foaf:Image" class="img-responsive" /&gt;&lt;/div&gt;
          &lt;/div&gt;
  

&lt;span&gt;&lt;span lang="" about="http://www.itnonline.com/users/timhodson" typeof="schema:Person" property="schema:name" datatype="" xml:lang=""&gt;tim.hodson&lt;/span&gt;&lt;/span&gt;

&lt;span&gt;Mon, 11/02/2026 - 15:34&lt;/span&gt;

            &lt;div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"&gt;&lt;p&gt;Oct. 28, 2026 — Clarius Mobile Health has announced 30 specialized AI models are now integrated into Clarius App 13.1. &lt;/p&gt;
&lt;p&gt;Since introducing its first on-device AI model in 2020, Clarius has rapidly expanded its AI portfolio across clinical measurements, anatomical education, and intelligent workflows. With 30 integrated models, compared with 16 AI technologies reported in December 2025, Clarius is demonstrating the accelerating pace of its software-driven innovation.&lt;/p&gt;
&lt;p&gt;"The next era of ultrasound won't be defined by portability alone. It will be defined by intelligence," said Kris Dickie, chief technology officer at Clarius. "Thirty models is just the beginning. We've built the technology, expertise, and momentum to continuously advance what handheld ultrasound can do. We're not just making ultrasound more portable. We're redefining what clinicians can expect from it."&lt;/p&gt;
&lt;h4&gt;Intelligent Ultrasound&lt;/h4&gt;
&lt;p&gt;Clarius' expanding AI portfolio brings intelligence into three essential aspects of the clinical ultrasound experience:&lt;/p&gt;
&lt;ol&gt;&lt;li&gt;
&lt;p&gt;AI THAT ENHANCES DIAGNOSTIC WORKFLOW — 12 Models:&lt;b&gt; &lt;/b&gt;Automates steps in clinical measurements across cardiac imaging, obstetrics, urology, and musculoskeletal medicine. From AI-assisted ejection fraction assessment to prostate and bladder volume measurements, these capabilities reduce manual tasks while keeping clinicians in control.&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;AI THAT BRINGS ANATOMY TO LIFE — 14 Models: Clarius T-Mode overlays anatomical illustrations and labels onto live ultrasound images, turning scans into visual learning opportunities that help clinicians recognize structures and build scanning confidence.&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;AI THAT SIMPLIFIES — 4 Models: Intelligent preset selection, voice commands, and speech-to-text capabilities streamline ultrasound workflows, reducing manual interactions so clinicians can focus on the examination, not the technology.&lt;/p&gt;
&lt;/li&gt;
&lt;/ol&gt;&lt;h4&gt;Continuous Innovation&lt;/h4&gt;
&lt;p&gt;Clarius combines on-device AI processing with a proprietary, in-house development platform designed for continuous innovation. AI models run directly on compatible smartphones and tablets, enabling supported capabilities without an internet connection during scanning. New capabilities can be delivered through software updates, extending the value of compatible existing scanners without requiring hardware replacement.&lt;/p&gt;
&lt;p&gt;"Our proprietary AI development platform has fundamentally changed the pace of innovation," added Dickie. "We can move from a clinical idea to a working AI model in a matter of weeks. Combined with our experience bringing regulated AI solutions to market, this allows us to accelerate innovation and put increasingly intelligent ultrasound capabilities into clinicians' hands through software."&lt;/p&gt;
&lt;p&gt;Clarius' AI innovation is supported by an established regulatory track record, including FDA-cleared AI models and CE-marked capabilities for European markets. Its AI is designed to simplify clinical workflows, support anatomical learning, and assist with measurements while keeping clinicians in control.&lt;/p&gt;
&lt;p&gt;With the industry's largest publicly documented integrated AI portfolio and an innovation engine built for speed, Clarius is advancing a new era of ultrasound where intelligence evolves continuously, capabilities expand through software, and sophisticated imaging becomes more accessible at the point of care.&lt;/p&gt;
&lt;h4&gt;Availability&lt;/h4&gt;
&lt;p&gt;Clarius App 13.1 is available for compatible Clarius wireless handheld ultrasound scanners. Feature availability varies by scanner, market, and regulatory authorization.&lt;/p&gt;
&lt;p&gt;To learn more about Clarius AI-powered ultrasound, visit &lt;a href="http://www.clarius.com"&gt;www.clarius.com&lt;/a&gt; and &lt;a href="https://clarius.com/ultrasound-ai/"&gt;Clarius Intelligence&lt;/a&gt;.&lt;/p&gt;
&lt;p&gt; &lt;/p&gt;
&lt;p&gt;&lt;img alt="Clarius Ultrasound App" data-entity-type="file" data-entity-uuid="c1b7c762-48ab-49a6-8352-2e0d3eb81632" height="75" src="http://www.itnonline.com/sites/default/files/inline-images/Clarius%20App%20sm.png" width="75" class="align-center" /&gt;&lt;/p&gt;&lt;p&gt; &lt;/p&gt;
&lt;/div&gt;
      
            &lt;div class="field field--name-field-publication-date field--type-datetime field--label-hidden field--item"&gt;&lt;time datetime="2026-11-02T21:34:48Z"&gt;Monday, November 2, 2026 - 15:34&lt;/time&gt;&lt;/div&gt;
      
      &lt;div class="field field--name-field-company field--type-entity-reference field--label-hidden field--items"&gt;
              &lt;div class="field--item"&gt;
&lt;div id="node-80736" data-history-node-id="80736" role="article" about="http://www.itnonline.com/company/clarius-mobile-health" class="node node-company is-promoted default clearfix"&gt;
  
    

  
  &lt;div class="content"&gt;
     
      &lt;/div&gt;

&lt;/div&gt;

&lt;/div&gt;
          &lt;/div&gt;
  </description>
  <pubDate>Mon, 02 Nov 2026 21:34:48 +0000</pubDate>
    <dc:creator>tim.hodson</dc:creator>
    <guid isPermaLink="false">91309 at http://www.itnonline.com</guid>
    </item>
<item>
  <title>SimonMed Launches Two New Lung Imaging Technologies</title>
  <link>http://www.itnonline.com/content/simonmed-launches-two-new-lung-imaging-technologies</link>
  <description>
      &lt;div class="field field--name-field-image field--type-image field--label-hidden field--items"&gt;
              &lt;div class="field--item"&gt;  &lt;img loading="lazy" src="http://www.itnonline.com/sites/default/files/SimonMed%204D.png" width="300" height="300" alt="SimonMed Launches Two New Lung Imaging Technologies" title="SimonMed Launches Two New Lung Imaging Technologies" typeof="foaf:Image" class="img-responsive" /&gt;&lt;/div&gt;
          &lt;/div&gt;
  

&lt;span&gt;&lt;span lang="" about="http://www.itnonline.com/users/timhodson" typeof="schema:Person" property="schema:name" datatype="" xml:lang=""&gt;tim.hodson&lt;/span&gt;&lt;/span&gt;

&lt;span&gt;Mon, 11/02/2026 - 14:28&lt;/span&gt;

            &lt;div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"&gt;&lt;p&gt;Nov.2, 2026 – &lt;a href="https://simonmed.com/"&gt;SimonMed &lt;/a&gt;has announced the clinical launch of two advanced lung imaging technologies, CT:VQ and LDAf, in partnership with global medical technology company &lt;a href="https://4dmedical.com/"&gt;4DMedical&lt;/a&gt;.&lt;/p&gt;
&lt;p&gt;Available at SimonMed locations nationwide, the technologies expand access to functional and quantitative lung analysis, helping physicians gain a more comprehensive understanding of lung health beyond what conventional CT imaging alone can reveal. &lt;/p&gt;
&lt;p&gt;As 4DMedical's first outpatient imaging-group partner, SimonMed is bringing these advanced capabilities into community-based imaging settings, reinforcing its commitment to making innovative medical technologies more widely accessible to physicians and the patients they serve. &lt;/p&gt;
&lt;p&gt;The announcement coincides with November’s COPD Awareness Month, highlighting the importance of improving the evaluation of respiratory conditions. For patients experiencing persistent shortness of breath, chronic cough or other unexplained respiratory symptoms, identifying the underlying cause can be challenging. These technologies provide additional information to support clinical assessment and care decisions. &lt;/p&gt;
&lt;p&gt;“Shortness of breath is a common symptom, but understanding its underlying cause isn’t always straightforward,” said Dr. Sean Raj, chief medical officer and chief innovation officer at SimonMed. “These technologies add functional and quantitative insights to chest CT, helping physicians look beyond structure for a more detailed picture of lung health to support the evaluation of conditions such as COPD, emphysema and asthma.” &lt;/p&gt;
&lt;h4&gt;Lung Health&lt;/h4&gt;
&lt;p&gt;Both FDA-cleared technologies use specialized software to analyze non-contrast chest CT imaging, providing complementary insights into lung health. &lt;/p&gt;
&lt;ul&gt;&lt;li&gt;CT:VQ maps ventilation and perfusion to show how air and blood flow through different regions of the lungs. Traditionally assessed through nuclear medicine scans, these functions can now be evaluated using CT— without injected contrast, radioactive tracers or specialized nuclear medicine equipment. &lt;/li&gt;
&lt;li&gt;LDAf quantifies low-density lung tissue and air trapping to support the evaluation of obstructive lung disease. &lt;/li&gt;
&lt;/ul&gt;&lt;p&gt;Physicians can order either analysis individually or together to support evaluation of patients with persistent respiratory symptoms, abnormal pulmonary function tests, or known or suspected lung disease.&lt;/p&gt;
&lt;p&gt;"At SimonMed, our goal is to make the most advanced imaging technologies accessible to more people, helping physicians make informed decisions and patients better understand their health," said Dr. John Simon, Founder and CEO of SimonMed. "Our partnership with 4DMedical is another example of how we're bringing meaningful innovation into outpatient care." &lt;/p&gt;
&lt;p&gt;“Bringing the newest, breakthrough lung imaging tools to the marketplace requires partners with vision and technical prowess,” declares Dr. Andreas Fouras, founder and CEO of 4DMedical. “SimonMed is exactly the right care provider to bring 4D’s advanced CT:VQ and LDAf to its outpatient imaging network. That gives physicians new and ready access to detailed, functional and quantitative lung insights for patients—and simultaneously extends 4D technology further into the U.S. market.” &lt;/p&gt;
&lt;p&gt;CT:VQ and LDAf are available by physician order at SimonMed locations nationwide. Insurance coverage varies by plan, and applicable copays, coinsurance and deductibles may apply. &lt;/p&gt;
&lt;p&gt; &lt;/p&gt;
&lt;p&gt;&lt;img alt="SimonMed 4D Lung Imaging" data-entity-type="file" data-entity-uuid="84a03a69-f870-41d9-8681-8b1e79f192e2" height="75" src="http://www.itnonline.com/sites/default/files/inline-images/SimonMed%204D%20sm.png" width="75" class="align-center" /&gt;&lt;/p&gt;&lt;p&gt; &lt;/p&gt;
&lt;p&gt; &lt;/p&gt;
&lt;p&gt; &lt;/p&gt;
&lt;/div&gt;
      
            &lt;div class="field field--name-field-publication-date field--type-datetime field--label-hidden field--item"&gt;&lt;time datetime="2026-11-02T20:28:49Z"&gt;Monday, November 2, 2026 - 14:28&lt;/time&gt;&lt;/div&gt;
      
      &lt;div class="field field--name-field-company field--type-entity-reference field--label-hidden field--items"&gt;
              &lt;div class="field--item"&gt;
&lt;div id="node-90930" data-history-node-id="90930" role="article" about="http://www.itnonline.com/company/simonmed-imaging" class="node node-company is-promoted default clearfix"&gt;
  
    

  
  &lt;div class="content"&gt;
     
      &lt;/div&gt;

&lt;/div&gt;

&lt;/div&gt;
          &lt;/div&gt;
  </description>
  <pubDate>Mon, 02 Nov 2026 20:28:49 +0000</pubDate>
    <dc:creator>tim.hodson</dc:creator>
    <guid isPermaLink="false">91308 at http://www.itnonline.com</guid>
    </item>
<item>
  <title>Artera's Breast Cancer Stratification Tool Recognized for Innovation</title>
  <link>http://www.itnonline.com/content/arteras-breast-cancer-stratification-tool-recognized-innovation</link>
  <description>
      &lt;div class="field field--name-field-image field--type-image field--label-hidden field--items"&gt;
              &lt;div class="field--item"&gt;  &lt;img loading="lazy" src="http://www.itnonline.com/sites/default/files/Artera%20new_4.png" width="360" height="238" alt="Artera's Breast Cancer Stratification Tool Recognized for Innovation" title="Artera's Breast Cancer Stratification Tool Recognized for Innovation" typeof="foaf:Image" class="img-responsive" /&gt;&lt;/div&gt;
          &lt;/div&gt;
  

&lt;span&gt;&lt;span lang="" about="http://www.itnonline.com/users/timhodson" typeof="schema:Person" property="schema:name" datatype="" xml:lang=""&gt;tim.hodson&lt;/span&gt;&lt;/span&gt;

&lt;span&gt;Fri, 10/30/2026 - 11:13&lt;/span&gt;

            &lt;div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"&gt;&lt;p xmlns="http://www.w3.org/1999/xhtml"&gt;Oct. 29, 2026 —&lt;a href="https://artera.ai/"&gt; Artera&lt;/a&gt;, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, has received Frost &amp; Sullivan’s 2026 North American Technology Innovation Leadership Recognition for AI-powered breast cancer risk stratification. The &lt;a href="https://www.frost.com/analytics/best-practices-recognition/2026-recognition-recipients/"&gt;recognition&lt;/a&gt; highlights Artera’s approach to translating multimodal AI and clinical evidence into personalized cancer risk insights.&lt;/p&gt;
&lt;p xmlns="http://www.w3.org/1999/xhtml"&gt;ArteraAI Breast uses digitized routine pathology images and patient clinical variables to stratify patients with early-stage HR-positive/HER2-negative invasive breast cancer into low- and high-risk groups based on their likelihood of distant metastasis, without requiring a separate specialized molecular assay.&lt;/p&gt;
&lt;p xmlns="http://www.w3.org/1999/xhtml"&gt;Frost &amp; Sullivan cited Artera’s combination of scientific rigor, regulatory progress, scalable technology, and integration into existing clinical workflows. Together, these capabilities support the company’s continued expansion of its AI platform across cancer types.&lt;/p&gt;
&lt;h4 xmlns="http://www.w3.org/1999/xhtml"&gt;ArteraAI Breast&lt;/h4&gt;
&lt;p xmlns="http://www.w3.org/1999/xhtml"&gt;In 2026, Artera expanded its platform beyond prostate cancer with U.S. Food and Drug Administration (FDA) clearance of ArteraAI Breast in May and CE Marking in Europe. The test combines routine hematoxylin and eosin (H&amp;E) pathology images with clinical data to provide prognostic information on distant metastasis risk. Its development and evaluation drew on data from six multinational Phase III randomized clinical trials, with performance evaluated across diverse scanners, laboratories, and care settings.&lt;/p&gt;
&lt;p xmlns="http://www.w3.org/1999/xhtml"&gt;“As AI-enabled precision oncology matures, sustaining competitive advantage increasingly depends on scaling impact without proportionally increasing infrastructure, workforce, or operating costs. Unlike traditional molecular diagnostics companies that expand through labs, sequencing equipment, and complex biological supply chains, Artera built a software-centric enterprise designed for efficient growth,” said Ashish Kaul, Industry Analyst, TechVision.&lt;/p&gt;
&lt;p xmlns="http://www.w3.org/1999/xhtml"&gt;“We’re honored to receive the Technology Innovation Leadership Recognition from Frost &amp; Sullivan,” said Andre Esteva, CEO and co-founder of Artera. “Artera is committed to commercializing MMAI with rigorous clinical evidence to give clinicians deeper insight into each patient’s individual risk. With ArteraAI Breast, we’re building on our foundation in prostate cancer to bring these insights to more patients and help inform treatment decisions across cancer care.”&lt;/p&gt;
&lt;p xmlns="http://www.w3.org/1999/xhtml"&gt;Each year, Frost &amp; Sullivan presents its Technology Innovation Leadership Recognition to the company it identifies as demonstrating outstanding underlying technology, product and customer success, and potential to drive future business value.&lt;/p&gt;
&lt;p xmlns="http://www.w3.org/1999/xhtml"&gt; &lt;/p&gt;
&lt;p&gt;&lt;img alt="Atera Breast Cancer Stratification" data-entity-type="file" data-entity-uuid="b451f438-9257-4bf2-9cfb-5352ef8b5487" height="65" src="http://www.itnonline.com/sites/default/files/inline-images/Artera%20logo_1.png" width="75" class="align-center" /&gt;&lt;/p&gt;&lt;p&gt; &lt;/p&gt;
&lt;/div&gt;
      
            &lt;div class="field field--name-field-publication-date field--type-datetime field--label-hidden field--item"&gt;&lt;time datetime="2026-10-30T16:13:40Z"&gt;Friday, October 30, 2026 - 11:13&lt;/time&gt;&lt;/div&gt;
      </description>
  <pubDate>Fri, 30 Oct 2026 16:13:40 +0000</pubDate>
    <dc:creator>tim.hodson</dc:creator>
    <guid isPermaLink="false">91307 at http://www.itnonline.com</guid>
    </item>
<item>
  <title>AZ Med X-ray AI Applications Now Available on RapidAI’s Enterprise Platform</title>
  <link>http://www.itnonline.com/content/az-med-x-ray-ai-applications-now-available-rapidai%E2%80%99s-enterprise-platform</link>
  <description>
      &lt;div class="field field--name-field-image field--type-image field--label-hidden field--items"&gt;
              &lt;div class="field--item"&gt;  &lt;img loading="lazy" src="http://www.itnonline.com/sites/default/files/RadpidAI%20new%20logo%20sq_0.png" width="300" height="300" alt="AZ Med X-ray AI Applications Now Available on RapidAI’s Enterprise Platform" title="AZ Med X-ray AI Applications Now Available on RapidAI’s Enterprise Platform" typeof="foaf:Image" class="img-responsive" /&gt;&lt;/div&gt;
          &lt;/div&gt;
  

&lt;span&gt;&lt;span lang="" about="http://www.itnonline.com/users/timhodson" typeof="schema:Person" property="schema:name" datatype="" xml:lang=""&gt;tim.hodson&lt;/span&gt;&lt;/span&gt;

&lt;span&gt;Thu, 10/29/2026 - 15:31&lt;/span&gt;

            &lt;div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"&gt;&lt;p&gt;Oct. 27, 2026 — &lt;a href="https://www.azmed.co/"&gt;AZmed&lt;/a&gt; has announced that its FDA-cleared AZtrauma and AZchest X-ray AI applications are available through &lt;a href="http://rapidai.com"&gt;RapidAI&lt;/a&gt;, via the Rapid Enterprise Platform. The applications join a portfolio of 50+ clinical solutions that support radiologists and care teams across the patient journey, bringing AZmed’s X-ray analysis capabilities into a connected platform used by more than 2,500 hospitals.&lt;/p&gt;
&lt;h4&gt;X-ray and AI&lt;/h4&gt;
&lt;p&gt;X-ray findings can shape urgent decisions about treatment and follow-up, making timely interpretation and communication essential. AI can help radiologists identify suspected abnormalities and prioritize exams for review, while a shared clinical platform makes those insights accessible to the care teams acting on them. This connects support for the radiologist’s read with the coordination needed for next steps in care. In the U.S., AZtrauma detects fractures, joint effusions and dislocations on musculoskeletal X-rays across adult and pediatric (ages ≥ 2) populations. AZchest covers five findings on frontal chest X-rays: lung nodules, consolidation, pneumothorax, pleural effusion and increased cardiothoracic ratio, with triage and notification for pneumothorax and pleural effusion.&lt;/p&gt;
&lt;p&gt;The integration gives teams a consistent way to access and act on AI findings across clinical specialties, reducing the need to navigate separate AI tools. Radiologists receive AZmed results and worklist prioritization through Rapid Navigator Pro, while emergency physicians and orthopedic teams access results through the Rapid Mobile App, giving them shared clinical context to coordinate next steps.&lt;/p&gt;
&lt;p&gt;For health systems, a single IT deployment simplifies adding and managing AZmed’s applications alongside RapidAI solutions. Rapid Edge Cloud provides resilient infrastructure, while Rapid Insights gives health systems centralized visibility into AI program utilization and performance to support oversight as they expand their use of clinical AI.&lt;/p&gt;
&lt;p&gt;“AZtrauma and AZchest are built to fit the way a radiology department already works, not to add another screen to it,” said Julien VIDAL, CEO of AZmed. “Through the Rapid Enterprise Platform, radiologists read with our results in the same place as the rest of their AI, and the emergency and orthopedic teams act on those same findings.”&lt;/p&gt;
&lt;p&gt;The collaboration advances AZmed’s expansion in the U.S., making its FDA-cleared X-ray AI available to health systems through RapidAI’s established clinical network.&lt;/p&gt;
&lt;p&gt; &lt;/p&gt;
&lt;p&gt;&lt;img alt="RapidAI X-ray" data-entity-type="file" data-entity-uuid="ae28a56c-4d47-4846-a9cb-bfe38fa47d7a" height="26" src="http://www.itnonline.com/sites/default/files/inline-images/RapidAI%20logo%20new.png" width="75" class="align-center" /&gt;&lt;/p&gt;&lt;p&gt; &lt;/p&gt;
&lt;/div&gt;
      
            &lt;div class="field field--name-field-publication-date field--type-datetime field--label-hidden field--item"&gt;&lt;time datetime="2026-10-29T20:31:47Z"&gt;Thursday, October 29, 2026 - 15:31&lt;/time&gt;&lt;/div&gt;
      </description>
  <pubDate>Thu, 29 Oct 2026 20:31:47 +0000</pubDate>
    <dc:creator>tim.hodson</dc:creator>
    <guid isPermaLink="false">91306 at http://www.itnonline.com</guid>
    </item>
<item>
  <title>CaptureWare Video for iPhone/iPod Now Available from Altamont Software</title>
  <link>http://www.itnonline.com/content/captureware-video-iphoneipod-now-available-altamont-software</link>
  <description>
      &lt;div class="field field--name-field-image field--type-image field--label-hidden field--items"&gt;
              &lt;div class="field--item"&gt;  &lt;img loading="lazy" src="http://www.itnonline.com/sites/default/files/Altamont%20Software%20CaptureWare.png" width="300" height="300" alt="CaptureWare Video for iPhone/iPod Now Available from Altamont Software" title="CaptureWare Video for iPhone/iPod Now Available from Altamont Software" typeof="foaf:Image" class="img-responsive" /&gt;&lt;/div&gt;
          &lt;/div&gt;
  

&lt;span&gt;&lt;span lang="" about="http://www.itnonline.com/users/timhodson" typeof="schema:Person" property="schema:name" datatype="" xml:lang=""&gt;tim.hodson&lt;/span&gt;&lt;/span&gt;

&lt;span&gt;Thu, 10/29/2026 - 13:12&lt;/span&gt;

            &lt;div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"&gt;&lt;p&gt;Oct. 27, 2026 — &lt;a href="https://altamont.com/"&gt;Altamont Software&lt;/a&gt; recently announced that &lt;a href="https://altamont.com/CaptureWareVideo.html"&gt;CaptureWare Video&lt;/a&gt;, its &lt;a href="https://altamont.com/news.html?p=altamont-software-unveils-medical-video-capture-innovation-to-facilitate-hospital-wide-integration-into-the-medical-record"&gt;enterprise medical video capture solution&lt;/a&gt;, is now available on iPhone and iPad for capturing medical video and still images at the bedside, in the clinic, and at any other point-of-care location.&lt;/p&gt;
&lt;p&gt;Since its introduction, CaptureWare Video has enabled healthcare providers to easily integrate scopes from every department across the enterprise. It captures, identifies and forwards this valuable clinical information directly to existing PACS, EHR and VNA systems. Extending the application to iOS devices expands its reach, enabling providers to capture video and images directly and securely from any clinical location using an iPad or iPhone camera. A mobile device also can be connected to any scope, eliminating the need for a desktop computer or costly video connection box.&lt;/p&gt;
&lt;p&gt;"This announcement upholds our commitment to provide healthcare organizations with a single Connectivity Platform for capturing any type of image or video from any source and incorporating it into the EMR," said Chris Barnett, President and Co-Founder of Altamont Software. "Bringing CaptureWare Video to mobile devices gives providers the flexibility to capture video and still images wherever care is delivered."&lt;/p&gt;
&lt;h4&gt;With CaptureWare Video on the iPhone and iPad, healthcare organizations can:&lt;/h4&gt;
&lt;ul&gt;&lt;li&gt;
&lt;p&gt;Capture medical video and still images using a smartphone or tablet.&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;Use a low-cost USB capture card to connect an iPad/iPhone to any scope.&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;Upload clinical images and video to PACS, VNA and the EMR.&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;Integrate medical video directly into Epic Lumens.&lt;/p&gt;
&lt;/li&gt;
&lt;/ul&gt;&lt;p&gt;CaptureWare Video on mobile devices extends the enterprise benefits that have defined the solution since its launch:&lt;/p&gt;
&lt;ul&gt;&lt;li&gt;
&lt;p&gt;Expands the capabilities of existing enterprise imaging IT infrastructure.&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;Eliminates scope vendor-specific PACS silos.&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;Based on cost-effective enterprise licensing.&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;Further reduces the need for costly video boxes.&lt;/p&gt;
&lt;/li&gt;
&lt;/ul&gt;&lt;p&gt;CaptureWare Video is built on Altamont Software's Connectivity Platform, which also supports DICOM SR integration, eForms, and document capture.&lt;/p&gt;
&lt;p&gt; &lt;/p&gt;
&lt;p&gt;&lt;img alt="Altamont CaptureWare iPhone iPad" data-entity-type="file" data-entity-uuid="d014afd9-58af-46d4-92e6-f0230c49146a" height="75" src="http://www.itnonline.com/sites/default/files/inline-images/Altamont%20Software%20CaptureWare%20sm.png" width="75" class="align-center" /&gt;&lt;/p&gt;&lt;p&gt; &lt;/p&gt;
&lt;/div&gt;
      
            &lt;div class="field field--name-field-publication-date field--type-datetime field--label-hidden field--item"&gt;&lt;time datetime="2026-10-29T18:12:06Z"&gt;Thursday, October 29, 2026 - 13:12&lt;/time&gt;&lt;/div&gt;
      
      &lt;div class="field field--name-field-company field--type-entity-reference field--label-hidden field--items"&gt;
              &lt;div class="field--item"&gt;
&lt;div id="node-82499" data-history-node-id="82499" role="article" about="http://www.itnonline.com/company/altamont-software" class="node node-company is-promoted default clearfix"&gt;
  
    

  
  &lt;div class="content"&gt;
     
      &lt;/div&gt;

&lt;/div&gt;

&lt;/div&gt;
          &lt;/div&gt;
  </description>
  <pubDate>Thu, 29 Oct 2026 18:12:05 +0000</pubDate>
    <dc:creator>tim.hodson</dc:creator>
    <guid isPermaLink="false">91305 at http://www.itnonline.com</guid>
    </item>
<item>
  <title>Bracco to Open U.S. Contrast Media Manufacturing Facility </title>
  <link>http://www.itnonline.com/content/bracco-open-us-contrast-media-manufacturing-facility</link>
  <description>
      &lt;div class="field field--name-field-image field--type-image field--label-hidden field--items"&gt;
              &lt;div class="field--item"&gt;  &lt;img loading="lazy" src="http://www.itnonline.com/sites/default/files/Bracco%20logo%20new_4.png" width="400" height="400" alt="Bracco to Build U.S. Contrast Media Manufacturing Facility " title="Bracco to Build U.S. Contrast Media Manufacturing Facility " typeof="foaf:Image" class="img-responsive" /&gt;&lt;/div&gt;
          &lt;/div&gt;
  

&lt;span&gt;&lt;span lang="" about="http://www.itnonline.com/users/timhodson" typeof="schema:Person" property="schema:name" datatype="" xml:lang=""&gt;tim.hodson&lt;/span&gt;&lt;/span&gt;

&lt;span&gt;Wed, 10/28/2026 - 11:26&lt;/span&gt;

            &lt;div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"&gt;&lt;p&gt;Oct. 27, 2026 &lt;b&gt;–&lt;/b&gt; &lt;a href="http://www.bracco.com"&gt;Bracco&lt;/a&gt; has announced plans to invest $230 million to establish its first U.S. manufacturing facility for injectable contrast media in Sanford, North Carolina. Expected to create 200 jobs, the investment marks a significant milestone in Bracco's global manufacturing strategy, expanding production capacity and strengthening supply chain resilience in the United States, the company's largest market.&lt;/p&gt;
&lt;p&gt;“For almost 100 years, Bracco has been guided by one purpose: improving people’s lives. The United States is our largest market and home to many of the patients we serve,” said Fulvio Renoldi Bracco, Vice Chairman and CEO of Bracco Imaging. “Producing injectable contrast media here in Sanford brings our supply closer to American hospitals and patients and makes it even more resilient. We chose North Carolina for its talent and life sciences ecosystem. As a family-owned company, we invest for the long term, and we look forward to growing with the Sanford community for decades to come.”&lt;/p&gt;
&lt;h4&gt;Contrast Media Facility&lt;/h4&gt;
&lt;p&gt;The new state-of-the-art sterile manufacturing facility will complement Bracco's established production operations across Europe, Asia and Canada, creating a more geographically diversified and resilient manufacturing network. With additional sterile manufacturing capacity in the United States, Bracco will be better positioned to meet growing demand, respond to customer needs and support reliable access to injectable contrast media used in diagnostic imaging.&lt;/p&gt;
&lt;p&gt;The facility will be developed with a focus on advanced manufacturing capabilities and the high standards of quality that underpin Bracco's global operations, supporting the company's mission to advance diagnostic imaging and improve patient care.&lt;i&gt; &lt;/i&gt;&lt;/p&gt;
&lt;p&gt;Bracco selected Sanford, North Carolina, for its skilled workforce, established life sciences ecosystem and supportive environment for advanced manufacturing. The investment is expected to create 200 jobs across manufacturing, engineering, technical operations, quality, warehousing and administrative functions, contributing to the continued growth of the state’s life sciences sector.&lt;/p&gt;
&lt;p&gt;The project builds on Bracco's nearly century-long history of innovation in diagnostic imaging and reflects its continued investment in the manufacturing capabilities needed to support healthcare professionals and patients worldwide.&lt;/p&gt;
&lt;p&gt; &lt;/p&gt;
&lt;p&gt;&lt;img alt="Bracco US Contrast Media Facility" data-entity-type="file" data-entity-uuid="db14c186-7f9c-46f4-9e43-f3200fff6475" height="75" src="http://www.itnonline.com/sites/default/files/inline-images/Bracco%20logo%20new_1.png" width="75" class="align-center" /&gt;&lt;/p&gt;&lt;p&gt; &lt;/p&gt;
&lt;/div&gt;
      
            &lt;div class="field field--name-field-publication-date field--type-datetime field--label-hidden field--item"&gt;&lt;time datetime="2026-10-28T16:26:36Z"&gt;Wednesday, October 28, 2026 - 11:26&lt;/time&gt;&lt;/div&gt;
      
      &lt;div class="field field--name-field-company field--type-entity-reference field--label-hidden field--items"&gt;
              &lt;div class="field--item"&gt;
&lt;div id="node-1504" data-history-node-id="1504" role="article" about="http://www.itnonline.com/company/bracco-diagnostics" class="node node-company is-promoted default clearfix"&gt;
  
    

  
  &lt;div class="content"&gt;
     
      &lt;/div&gt;

&lt;/div&gt;

&lt;/div&gt;
          &lt;/div&gt;
  </description>
  <pubDate>Wed, 28 Oct 2026 16:26:36 +0000</pubDate>
    <dc:creator>tim.hodson</dc:creator>
    <guid isPermaLink="false">91304 at http://www.itnonline.com</guid>
    </item>
<item>
  <title>HOPPR Releases Whole-Body Musculoskeletal X-ray Narrative Model</title>
  <link>http://www.itnonline.com/content/hoppr-releases-whole-body-musculoskeletal-x-ray-narrative-model</link>
  <description>
      &lt;div class="field field--name-field-image field--type-image field--label-hidden field--items"&gt;
              &lt;div class="field--item"&gt;  &lt;img loading="lazy" src="http://www.itnonline.com/sites/default/files/HOPPR%20new_1.png" width="219" height="209" alt="HOPPR Releases Whole-Body Musculoskeletal X-ray Narrative Model" title="HOPPR Releases Whole-Body Musculoskeletal X-ray Narrative Model" typeof="foaf:Image" class="img-responsive" /&gt;&lt;/div&gt;
          &lt;/div&gt;
  

&lt;span&gt;&lt;span lang="" about="http://www.itnonline.com/users/timhodson" typeof="schema:Person" property="schema:name" datatype="" xml:lang=""&gt;tim.hodson&lt;/span&gt;&lt;/span&gt;

&lt;span&gt;Wed, 10/28/2026 - 10:34&lt;/span&gt;

            &lt;div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"&gt;&lt;p&gt;Oct. 28, 2026 — HOPPR has announced the beta release of the &lt;a href="https://www.hoppr.ai/foundation-model-library/"&gt;HOPPR FS MSK Whole-Body Narrative Model&lt;/a&gt;, a vision-language foundation model that generates draft findings text for musculoskeletal (MSK) radiographs. The model processes up to three views per study and provides a software component for developers building radiology reporting and image-based workflow applications. Through &lt;a href="https://www.hoppr.ai/forward-deployed-services/"&gt;HOPPR Forward Deployed Services&lt;/a&gt; (FDS), HOPPR works with organizations to evaluate, customize, and integrate the model within their workflow.&lt;/p&gt;
&lt;p&gt;MSK radiography spans the body, from the cervical spine to the toes. The FS MSK Model was trained across the musculoskeletal system — including the spine, thorax and chest wall, upper extremity, and pelvis and lower extremity — giving developers one starting point for report drafting across anatomical regions.&lt;/p&gt;
&lt;p&gt;HOPPR trained the model on approximately 674,000 proprietary outpatient MSK studies, with the dataset balanced across body parts. The model focuses on describing abnormalities rather than normal anatomy. HOPPR evaluates the model against 26 MSK finding categories, including fracture, degenerative joint and spine changes, alignment, soft tissue, bone quality and lesions, and hardware.&lt;/p&gt;
&lt;p&gt;“Organizations shouldn't need a separate AI model for every bone and joint. Musculoskeletal imaging spans the whole body, and a single model trained across it gives developers a far stronger foundation to build on,” said Khan Siddiqui, MD, co-founder and CEO of HOPPR. “The FS MSK Model offers one whole-body model for generating draft findings text, and our Forward Deployed Services team works with each customer to adapt it to their data and workflows.”&lt;/p&gt;
&lt;h4&gt;Whole-Body Musculoskeletal X-ray Narrative Model&lt;/h4&gt;
&lt;p&gt;The FDS team brings together HOPPR machine learning scientists, software engineers, data scientists, and clinical experts who work alongside each organization. For the FS MSK Model, that work includes customizing the model with the customer's own data, designing the labeling workflows that support it, integrating the model into existing systems, and supporting validation testing in the customer's environment. HOPPR's secure infrastructure is HITRUST e1 certified and SOC 2 Type II attested, and operates under a Quality Management System.&lt;/p&gt;
&lt;p&gt;The model name, “FS,” honors Dr. Florence Ada Stoney (1870-1932), widely credited as the first woman radiologist in the United Kingdom. Stoney established an X-ray department at the Elizabeth Garrett Anderson Hospital for Women in 1902 and later led the X-ray department at Fulham Military Hospital during World War I.&lt;/p&gt;
&lt;p&gt;“Dr. Stoney practiced radiology when the field was young and few doors were open to women,” said Roger Boodoo, MD, Medical Director of AI at HOPPR. “Naming this model in her honor recognizes the people who helped build the discipline our work depends on.”&lt;/p&gt;
&lt;p&gt;The FS MSK Whole-Body Narrative Model is a software component, not a medical device. &lt;/p&gt;
&lt;p&gt;&lt;img alt="HOPPR X-ray" data-entity-type="file" data-entity-uuid="40285bdb-6bac-423c-b508-d8c757da8c1f" height="71" src="http://www.itnonline.com/sites/default/files/inline-images/HOPPR%20new_1.png" width="75" class="align-center" /&gt;&lt;/p&gt;&lt;p&gt; &lt;/p&gt;
&lt;/div&gt;
      
            &lt;div class="field field--name-field-publication-date field--type-datetime field--label-hidden field--item"&gt;&lt;time datetime="2026-10-28T15:34:19Z"&gt;Wednesday, October 28, 2026 - 10:34&lt;/time&gt;&lt;/div&gt;
      </description>
  <pubDate>Wed, 28 Oct 2026 15:34:19 +0000</pubDate>
    <dc:creator>tim.hodson</dc:creator>
    <guid isPermaLink="false">91303 at http://www.itnonline.com</guid>
    </item>

  </channel>
</rss>
